Clinical Trials
Open
Accrual
0%
SWOG Clinical Trial Number
S1934
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Status Notes
Open to enrollment 9/9/21.
Research Committee(s)
Lung Cancer
Activated
09-09-2021
ClinicalTrials.gov Registry Number
04989283
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S2013
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Status Notes
S2013 will open to accrual on August 16, 2021, effective 12:00 pm PST.
Research Committee(s)
Symptom Control and Quality of Life
Activated
08-16-2021
Open
Accrual
0%
SWOG Clinical Trial Number
S1912CD
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Status Notes
Activation - Effective 2:00 p.m. Eastern Time.
All protocol documents will be accessible from the S1912CD protocol abstract page on www.ctsu.org after activation on 7/26/2021(login required).
All protocol documents will be accessible from the S1912CD protocol abstract page on www.ctsu.org after activation on 7/26/2021(login required).
Research Committee(s)
Cancer Care Delivery
Activated
07-26-2021
ClinicalTrials.gov Registry Number
NCT 04960787
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2005
A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
Research Committee(s)
Myeloma
Lymphoma
Activated
06-24-2021
ClinicalTrials.gov Registry Number
04840602
Open
Phase
III
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Status Notes
CTSU/NRG-BR007 has been endorsed and activated by SWOG, effective 6/15/2021. CTSU/NRG-BR007 was activated by NRG Oncology, effective 6/7/21.
Research Committee(s)
Breast Cancer
Activated
06-07-2021
ClinicalTrials.gov Registry Number
04852887
Open
Phase
SWOG Clinical Trial Number
CTSU/ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
Status Notes
CTSU/ANHL1931 was temporarily closed to accrual on 6/24/21.
CTSU/ANHL1931 has been endorsed and activated by SWOG, effective 7/15/21. CTSU/ANHL1931 was activated by Children's Oncology Group, effective 6/7/21.
CTSU/ANHL1931 has been endorsed and activated by SWOG, effective 7/15/21. CTSU/ANHL1931 was activated by Children's Oncology Group, effective 6/7/21.
Research Committee(s)
Lymphoma
Activated
06-07-2021
ClinicalTrials.gov Registry Number
04759586